Study To Evaluate The Impact Of Difficult To Treat Sites On Biological Response In Moderate-To-Severe Plaque Psoriasis(PsO).

Pfizer

Status: Completed

Conditions: Plaque Psoriasis

Treatments: Drug: Enbrel

Study type: Observational

Funder types: Industry

Identifiers

NCT04428411

B1801416

Details and patient eligibility

About

This study is to evaluate available local data in Iraq patients with moderate-to-severe plaque psoriasis on Enbrel treatment with regards to efficacy, treatment for PsO who have difficult to treat sites at presentation.

Enrollment: 486 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Moderate-to-severe plaque psoriasis patients whom have been receiving etanercept for at least 1 year duration.
• Have difficult to treat sites at presentation.
• Age ≥18 years.
• No history of using other biological treatments, other than etanercept for the treatment of moderate-to-severe PsO.

Exclusion criteria

• Etanercept use for treatment of moderate-to-severe PsO less than 1 year duration.
• Previous use of another biological treatment for treatment of moderate-to-severe PsO.

Trial design

486 participants in 1 patient group

Patients with moderate to severe plaque psoriasis

Description:

Iraqi patients diagnosed with moderate to severe plaque psoriasis that received Enbrel as treatment for disease

Treatment:

Drug: Enbrel